Concomitant use of cyclophosphamide significantly increased the risk of cardiac dysfunction ( P = 0.048), while low BMI (<20 kg/m 2 ) and preexisting cardiac disease showed a trend towards increased risk of cardiac dysfunction ( P = 0.07 for both).
Multiple logistic regression analysis showed that cardiac disease as a risk factor almost reached statistical significance in contributing to doxorubicin-induced cardiotoxicity in our patients (regression coefficient = 4.088, P = 0.07).
Similarly lower BMI (< 20 kg/m 2 ) and presence of associated heart disease correlated with increased incidence of subclinical cardiotoxicity (regression coefficient = −4.321, P = 0.07; r = 4.09, P = 0.07), though they did not reach statistical significance.